ROQ.L
Roquefort Therapeutics plc [ROQ.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ROQ.L Stock Summary
In the News
ROQ.L Financial details
Company Rating
-
Market Cap
8.72M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
05 Jun 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
4.6
Current Ratio
15.75
Debt / Equity
0.41
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-85.71%
SMA50
-87.5%
SMA100
-85.71%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
129.15M
Shs Float
35.8M
-
-
-
-
Target Price
-
52W Range
0.0-11.75
52W High
-
52W Low
-
RSI
3
Rel Volume
-
Avg Volume
144.09K
Volume
Perf Week
9900%
Perf Month
-3.57%
Perf Quarter
-
Perf Half Y
-8.47%
-
-
-
-
Beta
-0.036246
-
-
Volatility
2.34%, 3.4%
Prev Close
9900%
Price
6.75
Change
9900%
ROQ.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2021-12-31 |
|---|---|---|
| Revenue per share | 0 | |
| Net income per share | 0 | |
| Operating cash flow per share | 0 | |
| Free cash flow per share | 0 | |
| Cash per share | 0 | |
| Book value per share | 0 | |
| Tangible book value per share | 0 | |
| Share holders equity per share | 0 | |
| Interest debt per share | 0 | |
| Market cap | 0 | |
| Enterprise value | -899.72K | |
| P/E ratio | 0 | |
| Price to sales ratio | 0 | |
| POCF ratio | 0 | |
| PFCF ratio | 0 | |
| P/B Ratio | 0 | |
| PTB ratio | 0 | |
| EV to sales | 0 | |
| Enterprise value over EBITDA | 0 | |
| EV to operating cash flow | 0 | |
| EV to free cash flow | 0 | |
| Earnings yield | 0 | |
| Free cash flow yield | 0 | |
| Debt to equity | 0.12 | |
| Debt to assets | 0.1 | |
| Net debt to EBITDA | 0 | |
| Current ratio | 15.75 | |
| Interest coverage | 0 | |
| Income quality | 0 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0.32 | |
| Capex to operating cash flow | 0 | |
| Capex to revenue | 0 | |
| Capex to depreciation | 0 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 0 | |
| ROIC | 0 | |
| Return on tangible assets | 0 | |
| Graham Net | 0 | |
| Working capital | 2.88M | |
| Tangible asset value | 2.6M | |
| Net current asset value | 2.6M | |
| Invested capital | 0 | |
| Average receivables | 0 | |
| Average payables | 0 | |
| Average inventory | 0 | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 0 | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0 | |
| ROE | 0 | |
| Capex per share | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2020-09-30 | 2021-06-30 | 2021-12-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | |
| Market cap | 2.19M | 0 | 0 | 0 | |
| Enterprise value | 2.07M | -880.45K | -899.72K | -3.33M | |
| P/E ratio | -72.24 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | |
| POCF ratio | -242.97 | 0 | 0 | 0 | |
| PFCF ratio | -242.97 | 0 | 0 | 0 | |
| P/B Ratio | 18.78 | 0 | 0 | 0 | |
| PTB ratio | 18.78 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -273.75 | 0 | 0 | 0 | |
| EV to operating cash flow | -230.2 | 0 | 0 | 0 | |
| EV to free cash flow | -230.2 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.02 | 0.12 | 0.41 | |
| Debt to assets | 0 | 0.02 | 0.1 | 0.29 | |
| Net debt to EBITDA | 15.19 | 0 | 0 | 0 | |
| Current ratio | 0 | 62.36 | 15.75 | 3.13 | |
| Interest coverage | 0 | 0 | 0 | 0 | |
| Income quality | 1.19 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.28 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | |
| ROIC | 0.07 | 0 | 0 | 0 | |
| Return on tangible assets | -0.07 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | |
| Working capital | 116.43K | 879.36K | 2.88M | 2.33M | |
| Tangible asset value | 116.43K | 879.36K | 4.08M | 2.05M | |
| Net current asset value | 116.43K | 879.36K | 2.6M | 2.05M | |
| Invested capital | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | -0.07 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 |
ROQ.L Frequently Asked Questions
What is Roquefort Therapeutics plc stock symbol ?
Roquefort Therapeutics plc is a GB stock and trading under the symbol ROQ.L
What is Roquefort Therapeutics plc stock quote today ?
Roquefort Therapeutics plc stock price is $6.75 today.
Is Roquefort Therapeutics plc stock public?
Yes, Roquefort Therapeutics plc is a publicly traded company.
Company Profile
- Volume Average 144.09K
- Market Capitalization 8.72M
- Employee 1
- CEO Mr. Trevor Ajanthan Reginald
- Headquarters London,GB
- IPO Date 2021-03-22
-
Website
https://www.roquefortinvest.com 
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
